Welcome

J&J Covid Vaccine Manufacturer Gets OK to Resume Production (1)

July 29, 2021, 3:30 PM

The U.S. Food and Drug Administration cleared Johnson & Johnson’s Covid-19 vaccine manufacturer Emergent BioSolutions Inc. to resume production of the shot after a series of mishaps that led it to halt manufacturing.

The Gaithersburg, Maryland-based contract manufacturer said in statement on Thursday that U.S. regulators decided to allow it to resume production after completing extensive reviews at its facility in Baltimore’s Bayview neighborhood. A Biden administration official said that the FDA decided to allow Emergent to resume production after visiting the facility earlier this week.

U.S. regulators have inspected the Bayview site at least three times since a cross-contaminated ...

To read the full article log in.

Learn more about a Bloomberg Law subscription.